

Teresa Lambe

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1298550/publications.pdf>

Version: 2024-02-01

123
papers

26,794
citations

20817

60
h-index

17105

122
g-index

159
all docs

159
docs citations

159
times ranked

31212
citing authors

#	ARTICLE	IF	CITATIONS
1	Manufacturing a chimpanzee adenovirusâ€¢vectored SARSâ€¢CoVâ€¢2 vaccine to meet global needs. <i>Biotechnology and Bioengineering</i> , 2022, 119, 48-58.	3.3	38
2	Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum. <i>Lancet, The</i> , 2022, 399, 234-236.	13.7	318
3	SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses. <i>Cell</i> , 2022, 185, 467-484.e15.	28.9	788
4	Response to Letter to the Editor by Ish et al. entitled â€¢COVID-19 vaccine equityâ€¢the need of the hourâ€¢™. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2022, , .	0.5	0
5	Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial. <i>Lancet, The</i> , 2022, 399, 36-49.	13.7	161
6	Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study. <i>Lancet, The</i> , 2022, 399, 521-529.	13.7	314
7	Detection and quantification of antibody to SARS CoV 2 receptor binding domain provides enhanced sensitivity, specificity and utility. <i>Journal of Virological Methods</i> , 2022, 302, 114475.	2.1	8
8	CMV-associated T cell and NK cell terminal differentiation does not affect immunogenicity of ChAdOx1 vaccination. <i>JCI Insight</i> , 2022, 7, .	5.0	6
9	Divergent trajectories of antiviral memory after SARS-CoV-2 infection. <i>Nature Communications</i> , 2022, 13, 1251.	12.8	20
10	The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 beta (B.1.351) and other variants of concern in preclinical studies. <i>EBioMedicine</i> , 2022, 77, 103902.	6.1	23
11	Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV. <i>JCI Insight</i> , 2022, 7, .	5.0	26
12	Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: Three month analyses of the COV-BOOST trial.. <i>Journal of Infection</i> , 2022, 84, 795-813.	3.3	43
13	Why do breakthrough COVID-19 infections occur in the vaccinated?. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2022, 115, 67-68.	0.5	2
14	Potent cross-reactive antibodies following Omicron breakthrough in vaccinees. <i>Cell</i> , 2022, 185, 2116-2131.e18.	28.9	105
15	Viral vector vaccines. <i>Current Opinion in Immunology</i> , 2022, 77, 102210.	5.5	28
16	Fatal COVID-19 outcomes are associated with an antibody response targeting epitopes shared with endemic coronaviruses. <i>JCI Insight</i> , 2022, 7, .	5.0	24
17	Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum. <i>Cell</i> , 2022, 185, 2422-2433.e13.	28.9	532
18	An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females. <i>EBioMedicine</i> , 2022, 81, 104128.	6.1	8

#	ARTICLE	IF	CITATIONS
19	Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. <i>Lancet, The</i> , 2021, 397, 99-111.	13.7	3,887
20	Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Kenyan blood donors. <i>Science</i> , 2021, 371, 79-82.	12.6	247
21	Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses. <i>Nature Medicine</i> , 2021, 27, 279-288.	30.7	265
22	T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. <i>Nature Medicine</i> , 2021, 27, 270-278.	30.7	473
23	MAIT cell activation augments adenovirus vector vaccine immunogenicity. <i>Science</i> , 2021, 371, 521-526.	12.6	88
24	A booster dose enhances immunogenicity of the COVID-19 vaccine candidate ChAdOx1 nCoV-19 in aged mice. <i>Med</i> , 2021, 2, 243-262.e8.	4.4	62
25	Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. <i>Lancet, The</i> , 2021, 397, 881-891.	13.7	979
26	The Integration of Human and Veterinary Studies for Better Understanding and Management of Crimean-Congo Haemorrhagic Fever. <i>Frontiers in Immunology</i> , 2021, 12, 629636.	4.8	8
27	ChAdOx1-vectored Lassa fever vaccine elicits a robust cellular and humoral immune response and protects guinea pigs against lethal Lassa virus challenge. <i>Npj Vaccines</i> , 2021, 6, 32.	6.0	30
28	Native-like SARS-CoV-2 Spike Glycoprotein Expressed by ChAdOx1 nCoV-19/AZD1222 Vaccine. <i>ACS Central Science</i> , 2021, 7, 594-602.	11.3	118
29	T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses. <i>Nature Communications</i> , 2021, 12, 2055.	12.8	102
30	Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. <i>Cell</i> , 2021, 184, 2348-2361.e6.	28.9	936
31	Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. <i>Lancet, The</i> , 2021, 397, 1351-1362.	13.7	540
32	Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera. <i>Cell</i> , 2021, 184, 2201-2211.e7.	28.9	442
33	Heterologous vaccination regimens with self-amplifying RNA and adenoviral COVID vaccines induce robust immune responses in mice. <i>Nature Communications</i> , 2021, 12, 2893.	12.8	104
34	ChAdOx1 nCoV-19 (AZD1222) vaccine candidate significantly reduces SARS-CoV-2 shedding in ferrets. <i>Npj Vaccines</i> , 2021, 6, 67.	6.0	47
35	Antibody evasion by the P.1 strain of SARS-CoV-2. <i>Cell</i> , 2021, 184, 2939-2954.e9.	28.9	519
36	Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. <i>New England Journal of Medicine</i> , 2021, 384, 1885-1898.	27.0	1,077

#	ARTICLE	IF	CITATIONS
37	Temporal trends of SARS-CoV-2 seroprevalence during the first wave of the COVID-19 epidemic in Kenya. <i>Nature Communications</i> , 2021, 12, 3966.	12.8	40
38	ChAdOx1 nCoV-19 protection against SARS-CoV-2 in rhesus macaque and ferret challenge models. <i>Communications Biology</i> , 2021, 4, 915.	4.4	15
39	Intranasal ChAdOx1 nCoV-19/AZD1222 vaccination reduces viral shedding after SARS-CoV-2 D614G challenge in preclinical models. <i>Science Translational Medicine</i> , 2021, 13, .	12.4	180
40	Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial. <i>Lancet HIV</i> , 2021, 8, e474-e485.	4.7	190
41	Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum. <i>Cell</i> , 2021, 184, 4220-4236.e13.	28.9	630
42	Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial. <i>Lancet</i> , 2021, 398, 856-869.	13.7	430
43	Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial. <i>Lancet HIV</i> , 2021, 8, e568-e580.	4.7	124
44	Immunological and pathological outcomes of SARS-CoV-2 challenge following formalin-inactivated vaccine in ferrets and rhesus macaques. <i>Science Advances</i> , 2021, 7, eabg7996.	10.3	20
45	Identification of immune correlates of fatal outcomes in critically ill COVID-19 patients. <i>PLoS Pathogens</i> , 2021, 17, e1009804.	4.7	39
46	AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein-specific T _H 1 response with a diverse TCR repertoire. <i>Science Translational Medicine</i> , 2021, 13, eabj7211.	12.4	80
47	Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. <i>Nature Medicine</i> , 2021, 27, 2032-2040.	30.7	900
48	Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002). <i>Lancet</i> , 2021, 398, 981-990.	13.7	214
49	Recombinant protein vaccines against SARS-CoV-2. <i>Lancet Infectious Diseases</i> , 2021, 21, 1337-1338.	9.1	6
50	ChAdOx1 nCoV-19 (AZD1222) protects Syrian hamsters against SARS-CoV-2 B.1.351 and B.1.1.7. <i>Nature Communications</i> , 2021, 12, 5868.	12.8	52
51	Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil. <i>Nature Communications</i> , 2021, 12, 5861.	12.8	38
52	Respiratory and Intramuscular Immunization With ChAdOx2-NPM1-NA Induces Distinct Immune Responses in H1N1pdm09 Pre-Exposed Pigs. <i>Frontiers in Immunology</i> , 2021, 12, 763912.	4.8	5
53	Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCoV-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. <i>Lancet</i> , 2021, 398, 2258-2276.	13.7	519
54	CD4 ⁺ T Follicular Helper Cells in Human Tonsils and Blood Are Clonally Convergent but Divergent from Non-Tfh CD4 ⁺ Cells. <i>Cell Reports</i> , 2020, 30, 137-152.e5.	6.4	74

#	ARTICLE	IF	CITATIONS
55	Modified Vaccinia Ankaraâ€“Vectored Vaccine Expressing Nucleoprotein and Matrix Protein 1 (M1) Activates Mucosal M1-Specific T-Cell Immunity and Tissue-Resident Memory T Cells in Human Nasopharynx-Associated Lymphoid Tissue. <i>Journal of Infectious Diseases</i> , 2020, 222, 807-819.	4.0	16
56	ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques. <i>Nature</i> , 2020, 586, 578-582.	27.8	840
57	Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. <i>Lancet, The</i> , 2020, 396, 467-478.	13.7	2,080
58	Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. <i>Lancet, The</i> , 2020, 396, 1979-1993.	13.7	1,196
59	Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19. <i>Npj Vaccines</i> , 2020, 5, 69.	6.0	121
60	Reduced Ebola vaccine responses in CMV+ young adults is associated with expansion of CD57+KLRG1+ T cells. <i>Journal of Experimental Medicine</i> , 2020, 217, .	8.5	31
61	A single dose of ChAdOx1 MERS provides protective immunity in rhesus macaques. <i>Science Advances</i> , 2020, 6, eaba8399.	10.3	89
62	The early landscape of coronavirus disease 2019 vaccine development in the UK and rest of the world. <i>Immunology</i> , 2020, 160, 223-232.	4.4	86
63	A Multi-Filovirus Vaccine Candidate: Co-Expression of Ebola, Sudan, and Marburg Antigens in a Single Vector. <i>Vaccines</i> , 2020, 8, 241.	4.4	12
64	Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial. <i>Lancet Infectious Diseases, The</i> , 2020, 20, 816-826.	9.1	182
65	Vaccination with viral vectors expressing NP, M1 and chimeric hemagglutinin induces broad protection against influenza virus challenge in mice. <i>Vaccine</i> , 2019, 37, 5567-5577.	3.8	33
66	Vaccination With Viral Vectors Expressing Chimeric Hemagglutinin, NP and M1 Antigens Protects Ferrets Against Influenza Virus Challenge. <i>Frontiers in Immunology</i> , 2019, 10, 2005.	4.8	48
67	Humoral Immunogenicity and Efficacy of a Single Dose of ChAdOx1 MERS Vaccine Candidate in Dromedary Camels. <i>Scientific Reports</i> , 2019, 9, 16292.	3.3	72
68	A single-dose ChAdOx1-vectored vaccine provides complete protection against Nipah Bangladesh and Malaysia in Syrian golden hamsters. <i>PLoS Neglected Tropical Diseases</i> , 2019, 13, e0007462.	3.0	46
69	Vaccine platforms for the prevention of Lassa fever. <i>Immunology Letters</i> , 2019, 215, 1-11.	2.5	43
70	HLA-E: exploiting pathogen-host interactions for vaccine development. <i>Clinical and Experimental Immunology</i> , 2019, 196, 167-177.	2.6	28
71	Heterologous Two-Dose Vaccination with Simian Adenovirus and Poxvirus Vectors Elicits Long-Lasting Cellular Immunity to Influenza Virus A in Healthy Adults. <i>EBioMedicine</i> , 2018, 29, 146-154.	6.1	100
72	A naturally protective epitope of limited variability as an influenza vaccine target. <i>Nature Communications</i> , 2018, 9, 3859.	12.8	32

#	ARTICLE	IF	CITATIONS
73	Clinical Advances in Viral-Vectored Influenza Vaccines. <i>Vaccines</i> , 2018, 6, 29.	4.4	35
74	The Threshold of Protection from Liver-Stage Malaria Relies on a Fine Balance between the Number of Infected Hepatocytes and Effector CD8+ T Cells Present in the Liver. <i>Journal of Immunology</i> , 2017, 198, 2006-2016.	0.8	17
75	A review of Phase I trials of Ebola virus vaccines: what can we learn from the race to develop novel vaccines?. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 2017, 372, 20160295.	4.0	33
76	ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice. <i>Vaccine</i> , 2017, 35, 3780-3788.	3.8	133
77	Chimpanzee adenoviral vectors as vaccines for outbreak pathogens. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 3020-3032.	3.3	67
78	Novel Bivalent Viral-Vectored Vaccines Induce Potent Humoral and Cellular Immune Responses Conferring Protection against Stringent Influenza A Virus Challenge. <i>Journal of Immunology</i> , 2017, 199, 1333-1341.	0.8	16
79	Protective efficacy of a novel simian adenovirus vaccine against lethal MERS-CoV challenge in a transgenic human DPP4 mouse model. <i>Npj Vaccines</i> , 2017, 2, 28.	6.0	81
80	Detection of Vaccine-Induced Antibodies to Ebola Virus in Oral Fluid. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw031.	0.9	13
81	Activation of cross-reactive mucosal T and B cell responses in human nasopharynx-associated lymphoid tissue in vitro by Modified Vaccinia Ankara-vector influenza vaccines. <i>Vaccine</i> , 2016, 34, 1688-1695.	3.8	13
82	Viral vectors as vaccine platforms: from immunogenicity to impact. <i>Current Opinion in Immunology</i> , 2016, 41, 47-54.	5.5	137
83	What Lies Beneath: Antibody Dependent Natural Killer Cell Activation by Antibodies to Internal Influenza Virus Proteins. <i>EBioMedicine</i> , 2016, 8, 277-290.	6.1	67
84	A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA. <i>New England Journal of Medicine</i> , 2016, 374, 1635-1646.	27.0	295
85	Enhancing cellular immunogenicity of MVA-vector influenza vaccines by utilizing the F11L endogenous promoter. <i>Vaccine</i> , 2016, 34, 49-55.	3.8	13
86	Measuring Cellular Immunity to Influenza: Methods of Detection, Applications and Challenges. <i>Vaccines</i> , 2015, 3, 293-319.	4.4	26
87	Emergency Ebola response: a new approach to the rapid design and development of vaccines against emerging diseases. <i>Lancet Infectious Diseases</i> , The, 2015, 15, 356-359.	9.1	32
88	Clinical Assessment of a Novel Recombinant Simian Adenovirus ChAdOx1 as a Vectored Vaccine Expressing Conserved Influenza A Antigens. <i>Molecular Therapy</i> , 2014, 22, 668-674.	8.2	165
89	Improved adjuvanting of seasonal influenza vaccines: Preclinical studies of <scp>MVA-NP+M</scp> 1 coadministration with inactivated influenza vaccine. <i>European Journal of Immunology</i> , 2013, 43, 1940-1952.	2.9	43
90	Immunity Against Heterosubtypic Influenza Virus Induced By Adenovirus And MVA Expressing Nucleoprotein And Matrix Protein-1. <i>Scientific Reports</i> , 2013, 3, 1443.	3.3	67

#	ARTICLE	IF	CITATIONS
91	DOCK8 is critical for the survival and function of NKT cells. <i>Blood</i> , 2013, 122, 2052-2061.	1.4	68
92	Preliminary Assessment of the Efficacy of a T-Cell-Based Influenza Vaccine, MVA-NP+M1, in Humans. <i>Clinical Infectious Diseases</i> , 2012, 55, 19-25.	5.8	224
93	T-Cell Responses in Children to Internal Influenza Antigens, 1 Year After Immunization With Pandemic H1N1 Influenza Vaccine, and Response to Revaccination With Seasonal Trivalent Inactivated Influenza Vaccine. <i>Pediatric Infectious Disease Journal</i> , 2012, 31, e86-e91.	2.0	23
94	Polyethyleneimine is a potent mucosal adjuvant for viral glycoprotein antigens. <i>Nature Biotechnology</i> , 2012, 30, 883-888.	17.5	189
95	Expression and Cellular Immunogenicity of a Transgenic Antigen Driven by Endogenous Poxviral Early Promoters at Their Authentic Loci in MVA. <i>PLoS ONE</i> , 2012, 7, e40167.	2.5	22
96	A T Cell-Inducing Influenza Vaccine for the Elderly: Safety and Immunogenicity of MVA-NP+M1 in Adults Aged over 50 Years. <i>PLoS ONE</i> , 2012, 7, e48322.	2.5	107
97	Novel Viral Vectored Vaccines for the Prevention of Influenza. <i>Molecular Medicine</i> , 2012, 18, 1153-1160.	4.4	24
98	DOCK8 is essential for T cell survival and the maintenance of CD8 ⁺ T cell memory. <i>European Journal of Immunology</i> , 2011, 41, 3423-3435.	2.9	105
99	DOCK8 deficiency impairs CD8 T cell survival and function in humans and mice. <i>Journal of Experimental Medicine</i> , 2011, 208, 2305-2320.	8.5	175
100	Potent CD8+ T-Cell Immunogenicity in Humans of a Novel Heterosubtypic Influenza A Vaccine, MVA-NP+M1. <i>Clinical Infectious Diseases</i> , 2011, 52, 1-7.	5.8	424
101	The Essential Role of DOCK8 in Humoral Immunity. <i>Disease Markers</i> , 2010, 29, 141-150.	1.3	24
102	The essential role of DOCK8 in humoral immunity. <i>Disease Markers</i> , 2010, 29, 141-50.	1.3	12
103	Themis is a member of a new metazoan gene family and is required for the completion of thymocyte positive selection. <i>Nature Immunology</i> , 2009, 10, 831-839.	14.5	108
104	Dock8 mutations cripple B cell immunological synapses, germinal centers and long-lived antibody production. <i>Nature Immunology</i> , 2009, 10, 1283-1291.	14.5	236
105	Identification of a Steap3 endosomal targeting motif essential for normal iron metabolism. <i>Blood</i> , 2009, 113, 1805-1808.	1.4	75
106	Vitiligo pathogenesis: autoimmune disease, genetic defect, excessive reactive oxygen species, calcium imbalance, or what else?. <i>Experimental Dermatology</i> , 2008, 17, 139-140.	2.9	148
107	Commentary 7. <i>Experimental Dermatology</i> , 2008, 17, 157-158.	2.9	0
108	Immune privilege or privileged immunity?. <i>Mucosal Immunology</i> , 2008, 1, 372-381.	6.0	111

#	ARTICLE	IF	CITATIONS
109	Limited Peripheral T Cell Energy Predisposes to Retinal Autoimmunity. <i>Journal of Immunology</i> , 2007, 178, 4276-4283.	0.8	54
110	MyD88-dependent autoimmune disease in Lyn-deficient mice. <i>European Journal of Immunology</i> , 2007, 37, 2734-2743.	2.9	54
111	DNA repair is limiting for haematopoietic stem cells during ageing. <i>Nature</i> , 2007, 447, 686-690.	27.8	475
112	B-cell Tolerance. <i>Transplantation</i> , 2006, 81, 308-315.	1.0	23
113	CITED1 homozygous null mice display aberrant pubertal mammary ductal morphogenesis. <i>Oncogene</i> , 2006, 25, 1532-1542.	5.9	46
114	Differential expression of connexin 43 in mouse mammary cells. <i>Cell Biology International</i> , 2006, 30, 472-479.	3.0	10
115	Spontaneous B cell hyperactivity in autoimmune-prone MRL mice. <i>International Immunology</i> , 2006, 18, 1127-1137.	4.0	24
116	CD4 T Cell-Dependent Autoimmunity against a Melanocyte Neoantigen Induces Spontaneous Vitiligo and Depends upon Fas-Fas Ligand Interactions. <i>Journal of Immunology</i> , 2006, 177, 3055-3062.	0.8	74
117	A RING-type ubiquitin ligase family member required to repress follicular helper T cells and autoimmunity. <i>Nature</i> , 2005, 435, 452-458.	27.8	777
118	Hyper IgE in New Zealand black mice due to a dominant-negative CD23 mutation. <i>Immunogenetics</i> , 2004, 56, 564-571.	2.4	31
119	High Glucose-altered Gene Expression in Mesangial Cells. <i>Journal of Biological Chemistry</i> , 2002, 277, 9707-9712.	3.4	88
120	Cellular and developmental aspects of androgenetic alopecia. <i>Experimental Dermatology</i> , 1998, 7, 235-248.	2.9	117
121	Efficacy of ChAdOx1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 VOC 202012/01 (B.1.1.7). <i>SSRN Electronic Journal</i> , 0, , .	0.4	36
122	Single Dose Administration, And The Influence Of The Timing Of The Booster Dose On Immunogenicity and Efficacy Of ChAdOx1 nCoV-19 (AZD1222) Vaccine. <i>SSRN Electronic Journal</i> , 0, , .	0.4	10
123	Reduced Neutralization of SARS-CoV-2 B.1.1.7 Variant from Naturally Acquired and Vaccine Induced Antibody Immunity. <i>SSRN Electronic Journal</i> , 0, , .	0.4	2